House approves SB 82 to require oversight of psychotropic prescriptions for foster children

On the House floor the sponsor described SB 82 as a set of reforms to child-welfare decision-making and clinical oversight. The sponsor said the bill expands evidence‑based safety and risk assessments for caseworkers, amends trafficking language to include patrons or solicitors of a child, and establishes “a psychotropic medication oversight program” to monitor certain foster children prescribed psychiatric medications.

The sponsor explained the oversight team will review cases meeting specific criteria — for example, a six‑year‑old or younger prescribed one or more psychotropic medications or a seven‑year‑old or older prescribed two or more — and will comprise a child psychiatrist and a psychiatric nurse practitioner employed through the Department of Health. The team’s role, as described on the floor, is consultative: to review medical records, consult with prescribers and, when appropriate, make recommendations to the child’s health‑care team and notify parents or foster parents of those recommendations.

Representatives asked whether the program would infringe on parental rights or hasten termination proceedings; the sponsor said the oversight is intended as watchful, consultative care and not to substitute for prescribers’ decisions or to penalize parents who decline recommendations.

The House opened and closed voting on third substitute SB 82 and recorded passage 70–0; the bill will be transmitted to the Senate for further consideration.

Direct quotes in this article are taken from the House floor transcript and are attributed to the sponsor as recorded there.